An observational study in Major Depressive Disorder, Suicide and Suicidal Ideation, sponsored by Unity Health Toronto. Suspended at 1 site in Canada. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Unity Health Toronto · Observational
Among 17 studies in Depressive Disorder, Major by Unity Health Toronto — 8 open to participants now, 9 under way, none of them phase 3. Depressive Disorder, Major · Unity Health Toronto.
Among the 17 studies in Depressive Disorder, Major by Unity Health Toronto, this one is one of 4 that started in 2023, is one of 6 observational ones, and was the 2nd registered.
3,041 studies on the registry are indexed under Depressive Disorder, Major; 588 are open to participants now.
This study's planned enrollment of 90 is below the median of 131 across 400 observational studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →8 of the 17 studies in Depressive Disorder, Major by Unity Health Toronto are open now, in 1 country. Each count lists the studies.
Of the 410 Depressive Disorder, Major studies recruiting now, 92 (22%) set no upper age limit and 292 (71%) stop at 75 or younger; 54 take children under 18; 98 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →17 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2023.
Median enrollment 30 across the 11 interventional studies, 94 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
Unity Health Toronto is the lead sponsor of 447 studies on the registry; 82 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
2 of the studies in Depressive Disorder, Major by Unity Health Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163625Unity Health TorontoThe Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression | 2026-12-31 |
| NCT05613972Unity Health TorontoIntegrated Suicide & Trauma Therapy for Suicide Risk | 2027-04 |
Among the 17 studies in Depressive Disorder, Major by Unity Health Toronto, from their registry updates:
Nothing recorded among them since 2026-09-25.
Since capability for suicide involves overriding potential pain, and the opioid system plays a strong role in controlling pain perception, it follows that capability for suicide may be impacted by the opioid system. The goal of the proposed research is to identify the neural network underlying capability for suicide in order to determine if it can be a target for identifying high-risk individuals and for intervention.
Little evidence exists distinguishing individuals with suicidal ideation (SI) from those at risk for suicidal behaviour, illustrating the need for more comprehensive biomarkers for clinicians to guide their treatment approach and for new treatment avenues. Current theories of suicide have suggested the importance of an individual's capability for suicide in predicting suicide attempt or death. Building on this, Yovell and colleagues (2016) provided important preliminary data that the opioid system affects suicide risk, but the neural mechanisms and their relationship to capability for suicide are unclear. The goal of the proposed research is to identify the neural network underlying capability for suicide using functional magnetic resonance imaging (fMRI) in order to determine if it can be a target for identifying high-risk individuals and for intervention.
Subjects will recruited from Mental Health Clinics at St. Michael's Hospital from Mood Disorders Clinics and self-referrals from advertisements in Mental Health Department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria for patients:
Healthy control inclusion criteria: Ages between 18 and 70 years, capable of giving , not pregnant or lactating, no lifetime history of Axis I/II disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will have no personal or family psychiatric history and no suicide attempts.
Procedure: fMRI
Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item \>=2).
Procedure: fMRI
An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
Neural network underlying acquired capability for suicide
Measure the correlation between acquired capability for suicide and brain activity during a pressure pain task using fMRI in patients
Time frame: 2 weeks
Correlation between pain task performance and acquired capability for suicide
Assess the association between pain task ratings and acquired capability for suicide in patients
Time frame: 2 weeks
Ran from Jan 2023 to primary completion in Apr 2025, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.